Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Newamsterdam Pharma Company (NAMS)

166 + Investors. Track Smart Money conviction in NAMS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -14
Streak
1Q ▼
Buyers last Q
52%

Smart Money Signals — NAMS

Based on 168 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their NAMS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 92% of 3.0Y peak

92% of all-time peak
168 funds currently hold this stock — 92% of the 3.0-year high of 182 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
🚀

Fast accumulation — +32% more funds vs a year ago

fund count last 6Q
+41 new funds entered over the past year (+32% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 52% buying

96 buying88 selling
Last quarter: 96 funds bought or added vs 88 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-32 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 25 → 22 → 57 → 25. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 32% entered in last year

■ 23% conviction (2yr+) ■ 46% medium ■ 32% new
Only 38 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
🚀

Acceleration phase — new buyers rushing in

26 → 25 → 22 → 57 → 25 new funds/Q
New funds entering each quarter: 25 → 22 → 57 → 25. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
📊

Mixed cohorts — 19% veterans, 43% new entrants

■ 19% veterans ■ 38% 1-2yr ■ 43% new
Of 177 current holders: 33 (19%) held 2+ years, 68 held 1–2 years, 76 (43%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds
42 of 166 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.0
out of 10
Moderate Exit Risk
Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — NAMS

In 2026 Q1, 96 hedge funds were net buyers of NAMS (25 opened a new position, 71 added to an existing one), while 88 reduced or exited (49 trimmed, 39 sold completely) — a 52% buyer ratio, indicating a slight buying edge. 36% of total institutional value in NAMS is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -14 funds (more exits than new entries). Total institutional holders: 168.

Hedge Fund Ownership: NAMS

How many hedge funds hold NAMS — quarterly history vs. share price
Quarterly hedge fund ownership of NAMS vs. share price

Market Analysis: NAMS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: NAMS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Newamsterdam Pharma Company (NAMS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much NAMS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 76d ago
NAMS
-2.4%
XLV
+4.3%

NAMS outperformed XLV by -6.7% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 31d ago
NAMS
-11.8%
XLV
+5.4%

Since the filing became public, NAMS outperformed XLV by -17.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Growing Institutional Interest

Quality funds are building positions — conviction is rising but not yet widespread.

23 top-rated funds 7 high-conviction
Consensus
6.0
/ 10
breadth
×
Elite
6.3
/ 10
conviction
Hedge Fund Positioning: NAMS
166 + Investors

Track Smart Money conviction in NAMS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 166 182 -8.79%
13F Shares 123M 119M 3.0%
Total Value $3.80B $4.18B -9.12%
New Positions 24 57 -33
Increased Positions 68 54 +14
Closed Positions 40 13 +27
Reduced Positions 46 50 -4
Total Calls 5 5 -
Total Puts 6 4 50.0%
PUT/CALL Ratio 1.2 0.8 Neutral

Statistics: NAMS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

166 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NAMS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 NAMS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Fcpm III Services B.V. 40.77% 9,198,900 $294.5M
2 Bain Capital Life Sciences Investors, LLC 21.09% 7,306,566 $233.9M
3 Frazier Life Sciences Management, L.P. 13.96% 16,943,774 $542.4M
4 Medicxi Ventures Management (Jersey) Ltd 8.72% 2,674,182 $85.6M
5 Ra Capital Management, L.P. 3.24% 9,550,191 $305.7M
6 Artia Global Partners LP 3.23% 503,936 $16.1M
7 First Turn Management, LLC 2.00% 558,336 $17.9M
8 Atle Fund Management AB 1.78% 94,796 $5.5M
9 Deerfield Management Company, L.P. 1.61% 4,264,789 $136.5M
10 Decheng Capital LLC 1.57% 325,057 $10.4M
11 Cormorant Asset Management, LP 1.53% 950,000 $30.4M
12 DCF Advisers, LLC 1.37% 160,600 $5.1M
13 Stempoint Capital LP 1.12% 180,658 $5.8M
14 Ishara Investments LP 1.12% 36,900 $1.2M
15 Rock Springs Capital Management LP 1.11% 588,794 $18.8M
16 Logos Global Management LP 0.96% 600,000 $19.2M
17 Maverick Capital Ltd 0.81% 2,186,402 $70.0M
18 Moody Aldrich Partners LLC 0.66% 114,975 $3.7M
19 Catalio Capital Management, LP 0.56% 83,554 $2.7M
20 Eversept Partners, LP 0.48% 285,764 $9.1M
21 AlphaCentric Advisors LLC 0.47% 14,656 $469K
22 Affinity Asset Advisors, LLC 0.45% 275,000 $8.8M
23 Lifetime Wealth Management P.C. 0.43% 23,500 $752K
24 Viking Global Investors LP 0.38% 4,203,567 $134.6M
25 PSP Research LLC 0.34% 15,000 $480K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Newamsterdam Pharma Company (NAMS)

What does the Smart Money Trend signal show for NAMS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their NAMS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for NAMS?

Slight buying edge — 52% buying: Last quarter: 96 funds bought or added vs 88 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for NAMS holders?

Strong quality — 36% AUM from major funds: 42 of 166 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NAMS?

Mostly new holders — 32% entered in last year: Only 38 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Newamsterdam Pharma Company (NAMS) following the 2026 Q1 hedge fund 13F filings?

As of today, NAMS has moved -11.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.4% for the XLV sector ETF — an outperformance of -17.2%. Since the quarter end (March 31, 2026), NAMS has gained -2.4% vs +4.3% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →